Drug doubles quit rate of smokers
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A CHANCE observation by a psychiatrist has led to the discovery of a new drug for smokers that is twice as effective as nicotine patches in helping them to quit.
Zyban is an anti-depressant that has the unusual side effect of reducing the craving for nicotine. When given to smokers trying to give up, it doubled the number who were still not smoking after one year compared with those who used nicotine patches alone.
The discovery of Zyban's action was made six years ago by Dr Linda Ferry, an American psychiatrist at the Loma Linda University, California, who noticed that patients she was treating with the drug seemed less inclined to smoke.
Her observation was greeted with scepticism by colleagues but she conducted a pilot study published in 1994, which appeared to confirm her hunch. She has since continued to press for recognition of the drug as a smoking cessation aid. Yesterday that recognition came in the shape of a study published in the New England Journal of Medicine of 900 smokers who tried to stop.
Of those given a nicotine patch 16 per cent were still not smoking a year later. But the figure rose to 30 per cent of those treated with Zyban.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments